临床荟萃

• 论著 • 上一篇    下一篇

表皮生长因子受体阳性肺腺癌患者癌组织中microRNA-451表达与预后

  

  1. 南阳市第一人民医院 肿瘤内科二病区,河南 南阳 473012
  • 出版日期:2018-06-05 发布日期:2018-06-25
  • 通讯作者: 通信作者:王同甫,Email:13838794578@163.com

Expression of microRNA451 and prognosis in lung adenocarcinoma patients with positive expression of EGFR

  1. Department of Oncology, Nanyang First People's Hospital, Nanyang 473012, China
  • Online:2018-06-05 Published:2018-06-25
  • Contact: Corresponding author: Wang Tongfu,Email:13838794578@163.com

摘要: 目的 分析表皮生长因子受体(EGFR)阳性肺腺癌患者癌组织中微小RNA(microRNAs)451表达与预后的关系。方法 经病理组织活检明确诊断的EGFR表达阳性的靶向治疗联合全身化疗肺腺癌患者67例。癌组织病理标本经逆转录后行实时定量聚合酶链反应测microRNA451表达,根据microRNA451中位数分为高表达组与低表达组。比较两组化疗不良反应的发生率及其生存期的差异。结果 高表达组在化疗过程中发生3度、4度骨髓抑制的情况较低表达组低(χ2=5.382,P=0.020;χ2=4.947,P=0.026);高表达组在化疗过程中发生3度、4度消化道反应较低表达组低(χ2=7.208,P=0.007;χ2=6.211,P=0.013)。两组生存期比较,高表达组中位无进展生存时间(PFS)为12.3个月,低表达组中位PFS为9.0个月,两组比较差异有统计学意义(χ2=9.582,P=0.002)。高表达组中位总生存期(OS)为12.3个月,低表达组中位OS为11.5个月,两组比较差异有统计学意义(χ2=5.749,P=0.016)。结论 EGFR阳性表达的靶向治疗联合全身化疗肺腺癌microRNA451高表达患者化疗不良反应轻,生存期长。

关键词: 肺腺癌, 受体, 表皮生长因子, 微小RNA

Abstract: Objective  To analyze the relationship between the expression of RNA (microRNAs) 451 and prognosis in patients with positive expression of epidermal growth factor receptor (EGFR). Methods  A total of 67 lung adenocarcinoma patients with systemic chemotherapy and targeted therapy with positive EGFR expression confirmed by pathological biopsy were enrolled. After RTqPCR (realtime quantitative polymerase chain reaction), the pathological specimens of cancer tissues were examined for microRNA451 expression, and were divided into high expression group and low expression group based on the median expression of microRNA451. The incidence of adverse reactions to chemotherapy was compared between the two groups, as well as their differences in survival.Results  The 3 and 4 degree myelosuppression in the high expression group was lower than that in the low expression group (χ2=5.382, P=0.020; χ2=4.947, P=0.026), and the low expression group was low (χ2=7.208, P=0.007; χ2=6.211, P=0.013)  in the high expression group in the course of chemotherapy with 3 and 4 degrees of digestive tract reaction. In the two groups, the median PFS in the high expression group was 12.3  months, and the middle PFS in the low expression group was 9 months. The two groups had a statistically significant difference (χ2=9.582, P=0.002). The median overall survival (OS) in the high expression group was 12.3 months, while the median OS in the low expression group was 11.5 months, and the difference between the two groups was statistically significant (χ2=5.749, P=0.016).Conclusion  Targeted therapy with positive expression of EGFR combined with systemic chemotherapy in patients with high expression of microRNA451 in lung adenocarcinoma has mild adverse reactions and a long survival time.

Key words: lung adenocarcinoma, receptor, epidermail growth factor, microRNA